WILMINGTON, Del.--(BUSINESS WIRE)--Incyte (Nasdaq:INCY) announced today that it will present at the following investor conferences during the month of March: TD Cowen 46th Annual Health Care Conferenc
Cookson Peirce and Co. Inc. bought a new stake in Incyte Corporation (NASDAQ: INCY) during the undefined quarter, according to the company in its most recent 13F filing with the SEC. The fund bought 1
Baird Chautauqua International Growth Fund underperformed its benchmark as stock selection in health care and consumer discretionary detracted most from relative returns. Fanuc reported September quar

Incyte Q4 Earnings Call Highlights

05:34am, Thursday, 12'th Feb 2026
Incyte (NASDAQ: INCY) executives highlighted stronger-than-expected 2025 commercial performance, an increasingly late-stage pipeline, and multiple regulatory milestones during the company's fourth qua
Incyte experienced an 8.2% sell-off after 2026 guidance appeared to miss consensus by $680M, but this was due to a royalties accounting nuance. Adjusted for royalties, INCY's 2026 sales guidance is ne
Incyte Corporation (INCY) Q4 2025 Earnings Call Transcript
Release Date: February 10, 2026For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Incyte Corp
Incyte posts a Q4 EPS miss but a 28% revenue jump, fueled by Jakafi and Opzelura strength, as product sales top estimates.
While the top- and bottom-line numbers for Incyte (INCY) give a sense of how the business performed in the quarter ended December 2025, it could be worth looking at how some of its key metrics compare

Incyte (INCY) Q4 Earnings Lag Estimates

09:15am, Tuesday, 10'th Feb 2026
Incyte (INCY) came out with quarterly earnings of $1.8 per share, missing the Zacks Consensus Estimate of $1.94 per share. This compares to earnings of $1.43 per share a year ago.
Incyte forecast annual sales below Wall Street estimates on Tuesday with its key growth driver Opzelura expected to underperform, raising concerns about the drugmaker's ability to offset looming paten
WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Incyte Reports Fourth Quarter and Full Year 2025 Financial Results.
Profund Advisors LLC cut its position in shares of Incyte Corporation (NASDAQ: INCY) by 28.8% during the third quarter, according to the company in its most recent disclosure with the Securities and E
Let's look at five pharma and biotech companies, AZN, INCY, GILD, VRTX and MRNA, which are scheduled to release their fourth-quarter 2025 results this week.
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Click to get the best stock tips daily for free!

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE